

OFFICIAL**McGREGOR & ADLER, LLP****FAX RECEIVED**P.O. BOX 710509
HOUSTON, TEXAS 77271-0509**JUN 28 1999**WRITER'S DIRECT DIAL
(713)-777-2321
WRITER'S DIRECT FACS.
(713)-777-6908
E. MAIL: BAADLER@flash.net**GROUP 1600**
INTELLECTUAL PROPERTY LAW
(PATENT, BIOTECHNOLOGY, COMPUTER,
TRADEMARK & TRADE SECRET LAW)**June 25, 1999****FACSIMILE COVER SHEET****PLEASE DELIVER TO:** **Examiner Gabriele E. Bugaisky****COMPANY:** **U.S. PTO/ ART UNIT 1643****FACSIMILE NUMBER:** **(703) 308-4242****NUMBER OF PAGES (COUNTING COVER SHEET):****4****FROM:** **Benjamin A. Adler****MESSAGE:** Please deliver the attached to Examiner Bugaisky. Attached is a Supplemental Response after Final Office Action Under 37 CFR 1.116 for Novel Extracellular Serine Protease, Serial No: 08/915,659 (O'Brien, T. D6020).

CONFIDENTIALITY NOTICE: Unless otherwise indicated or obvious from the nature of this transmittal, the information contained in this facsimile is attorney privileged and confidential information intended for the use of the individual or entity named above. If the reader is not the intended recipient or an employee or agent responsible for delivery, you are hereby notified that any dissemination, distribution or copying of this communication is strictly prohibited. If you receive this communication in error, please immediately notify Dr. Benjamin Adler at (713) 777-2321 and promptly return the facsimile. Thank you.

cc: BAA.

RECEIVED

Jun. 25 1999 04:14PM P2

JUN 28 1999

GROUP 1800

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: T. O'Brien *et al.*§
§
§
§
§
§

ART UNIT: 1653

FILED: August 21, 1997

EXAMINER:

SERIAL NO.: 08/915,659

G. E. Bugaisky

FOR: Novel Extracellular Serine Protease

DOCKET: D6020

The Assistant Commissioner of Patents and Trademarks
Box AF
Washington, DC 20231

Certificate of Facsimile Transmission

I certify that this response was transmitted via Facsimile to Examiner
G. E. Bugaisky at the Patent Office on the date indicated below.

June 25, 1999

Date

Benjamin Aaron Adler
Benjamin Aaron Adler, Ph.D., J.D.

SUPPLEMENTARY RESPONSE AFTER FINAL

Dear Sir:

Responsive to the Final Office Action mailed May 17, 1999 and
the June 25, 1999 telephone conversation with the Examiner Bugaisky,
please enter the following amendments. Reconsideration of this
application as amended is respectfully requested.

IN THE CLAIMS:

Please amend claim 1 as follows:

1. (thrice amended) DNA encoding a Tumor Antigen
Derived Gene-14 (TADG-14) protein, wherein said protein has the